Showing 1 - 7 results of 7 for search 'Miguel J. Gil', query time: 0.76s Refine Results
  1. 1
    Bevacizumab for the Treatment of Glioblastoma

    Bevacizumab for the Treatment of Glioblastoma by Miguel J. Gil-Gil, Carlos Mesia, Montserrat Rey, Jordi Bruna

    Published 2013-06-01
    Get full text
    Article
  2. 2
    Bevacizumab for the Treatment of Glioblastoma

    Bevacizumab for the Treatment of Glioblastoma by Miguel J. Gil-Gil, Carlos Mesia, Montserrat Rey, Jordi Bruna

    Published 2013-01-01
    Get full text
    Article
  3. 3
    Risk of Ischemic Stroke Associated With Calcium Supplements With or Without Vitamin D: A Nested Case‐Control Study

    Risk of Ischemic Stroke Associated With Calcium Supplements With or Without Vitamin D: A Nested Case‐Control Study by Francisco J. de Abajo, Sara Rodríguez‐Martín, Antonio Rodríguez‐Miguel, Miguel J. Gil

    Published 2017-05-01
    Get full text
    Article
  4. 4
    Perfil Clínico-Epidemiológico de Pacientes que inician Terapia Intensiva con Estatinas para La Prevención Secundaria de Enfermedad Vascular en España

    Perfil Clínico-Epidemiológico de Pacientes que inician Terapia Intensiva con Estatinas para La Prevención Secundaria de Enfermedad Vascular en España by Diego Macías Saint Gerons, César de la Fuente Honrubia, Diana González Bermejo, Dolores Montero, Miguel J. Gil, Antonio Salvador Sanz, Fernando de Andrés Trelles, Ferrán Catalá López

    Published 2015-01-01
    Get full text
    Article
  5. 5
    Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

    Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. by David Molina, Julián Pérez-Beteta, Alicia Martínez-González, Juan M Sepúlveda, Sergi Peralta, Miguel J Gil-Gil, Gaspar Reynes, Ana Herrero, Ramón De Las Peñas, Raquel Luque, Jaume Capellades, Carmen Balaña, Víctor M Pérez-García

    Published 2016-01-01
    Get full text
    Article
  6. 6
    Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

    Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study by David Mills, Hui Gan, Jeffrey Raizer, Patrick Yung Wen, Warren Mason, John DeGroot, Valerie Donnet, Mona El-Hashimy, Mark Rosenthal, Paul M Clement, Mario Campone, Miguel J Gil-Gil, Olivier Chinot, Ahmed Idbaih, Estela Pineda

    Published 2020-10-01
    Get full text
    Article
  7. 7
    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina... by Miguel J. Gil-Gil, Meritxell Bellet, Milana Bergamino, Serafín Morales, Agustí Barnadas, Luís Manso, Cristina Saura, Adela Fernández-Ortega, Elena Garcia-Martinez, Noelia Martinez-Jañez, Mireia Melé, Patricia Villagrasa, Pamela Celiz, X. Perez Martin, Eva Ciruelos, Sonia Pernas

    Published 2021-07-01
    Get full text
    Article

Search Tools: